Fresenius Kabi Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FRESENIUS KABI, and when can generic versions of FRESENIUS KABI drugs launch?
FRESENIUS KABI has three hundred and nine approved drugs.
There are twenty-three US patents protecting FRESENIUS KABI drugs. There are two tentative approvals on FRESENIUS KABI drugs.
There are one hundred and twenty-nine patent family members on FRESENIUS KABI drugs in twenty-five countries and four hundred and sixty-six supplementary protection certificates in seventeen countries.
Summary for Fresenius Kabi
| International Patents: | 129 |
| US Patents: | 23 |
| Tradenames: | 254 |
| Ingredients: | 188 |
| NDAs: | 309 |
| Patent Litigation for Fresenius Kabi: | See patent lawsuits for Fresenius Kabi |
| PTAB Cases with Fresenius Kabi as petitioner: | See PTAB cases with Fresenius Kabi as petitioner |
| PTAB Cases with Fresenius Kabi as patent owner: | See PTAB cases with Fresenius Kabi as patent owner |
Drugs and US Patents for Fresenius Kabi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | DIAZEPAM | diazepam | INJECTABLE;INJECTION | 214745-001 | Nov 10, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | BENZTROPINE MESYLATE | benztropine mesylate | INJECTABLE;INJECTION | 090233-001 | Jul 28, 2009 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | TOPOTECAN HYDROCHLORIDE | topotecan hydrochloride | INJECTABLE;INJECTION | 091376-001 | Nov 29, 2010 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Fresenius Kabi Usa | ROMIDEPSIN | romidepsin | POWDER;INTRAVENOUS | 206254-001 | Oct 12, 2021 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | BORTEZOMIB | bortezomib | POWDER;INTRAVENOUS | 205004-001 | Nov 6, 2017 | DISCN | No | No | 8,962,572 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Fresenius Kabi
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | DIPRIVAN | propofol | INJECTABLE;INJECTION | 019627-002 | Jun 11, 1996 | 5,731,355*PED | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-001 | May 1, 1998 | 8,162,915 | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-004 | Sep 24, 1996 | 4,870,086 | ⤷ Sign Up |
| Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-005 | Apr 30, 2009 | 6,589,960 | ⤷ Sign Up |
| Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-003 | May 1, 1998 | 5,670,524 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FRESENIUS KABI drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 2 mg/mL | ➤ Subscribe | 2011-06-22 |
| ➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2011-11-04 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | Injection | 2 mg/mL, 100 mL | ➤ Subscribe | 2015-01-30 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Oral Solution | 5 mg/5mL | ➤ Subscribe | 2011-02-25 |
| ➤ Subscribe | Tablets | 2 mg, 4 mg, and 8 mg | ➤ Subscribe | 2013-08-05 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Injection | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials | ➤ Subscribe | 2006-11-13 |
| ➤ Subscribe | Injection | 2 mg/mL, 200 mL | ➤ Subscribe | 2015-09-03 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
International Patents for Fresenius Kabi Drugs
Supplementary Protection Certificates for Fresenius Kabi Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | 10C0038 | France | ⤷ Sign Up | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| 0206283 | C980016 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 |
| 1425001 | SPC/GB14/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VILANTEROL OR SALTS OR SOLVATES THEREOF (I.E., 4-((1R)-2-((6-(2-((2,6-DICHLOROBENZYL)OXY)ETHOXY)HEXYL)AMINO)-1-HYDROXYETHYL)-2-(HYDROXYMETHYL)PHENOL OR SALTS OR SOLVATES THEREOF); REGISTERED: UK EU/1/13/886/001 20131114; UK EU/1/13/886/002 20131114; UK EU/1/13/886/003 20131114; UK EU/1/13/886/004 20131114; UK EU/1/13/886/005 20131114; UK EU/1/13/886/006 20131114 |
| 3347352 | 2290051-8 | Sweden | ⤷ Sign Up | PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819 |
| 1744764 | 2018/042 | Ireland | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
